Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Living Cell Technologies’ (LCT) CEO retires and its Chair Professor Bernie Tuch steps up as interim CEO
  • Dr Ken Taylor retires following seven years as CEO and three years on the board of the Australasian biotechnology company
  • Professor Tuch, who was chairman of the Remuneration and Nomination Committee, will take on the interim position as of July 16
  • Looking forward, the company announced it has been undertaking confidential discussions to explore opportunities for new projects and partnerships
  • Shares are trading 7.14 per cent higher at 1.5 cents at 10:04 am AEST

Living Cell Technologies’ (LCT) CEO has retired, and its Chair Professor Bernie Tuch is stepping up as interim CEO.

Dr Ken Taylor retired today, following seven years as CEO of the Australasian biotechnology company.

He has also subsequently left the board of LCT after being appointed in August 2018.

Professor Tuch, who was chairman of the Remuneration and Nomination Committee will take on the interim position as of July 16.

Commenting on Dr Ken Taylors retirement, professor Tuch said the company is extremely grateful for his contribution and leadership.

“LCT has benefited greatly from his experience and international connections”

According to LCT, the interim CEO has been supervising a bioengineering diabetes cell therapy project at the University of Technology Sydney. 

Previously, he was a senior scientist with CSIRO Australia.

He is noted as having previous scientific collaborations with LCT and believes he knows the company’s direction intimately. 

Living Cell Technologies is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson’s disease.

Looking forward, the company announced it has been undertaking confidential discussions to explore opportunities for new projects and partnerships.

Shares were trading 7.14 per cent higher at 1.5 cents at 10:04 am AEST.

LCT by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.